Literature DB >> 8058650

Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody.

M Paborji1, N L Pochopin, W P Coppola, J B Bogardus.   

Abstract

Chimeric L6 is a mouse-human monoclonal antibody specific for tumor cell-associated antigens. The factors affecting the physical and chemical stability of chimeric L6 were assessed at elevated temperatures (30-60 degrees C) and by multiple freezing and thawing. Three routes of degradation were observed: chemical degradation to smaller molecular weight species, irreversible aggregation, and formation of a reversible dimer. The specific pathway depended on the stress condition applied and the pH, with maximal overall stability to both thermal stress and multiple freezing/thawing observed at about pH 5.5. Other factors including antibody concentration, buffer concentration, NaCl concentration, and agitation had minimal influence on the stability. Commonly used sugars, polyhydric alcohols, and amino acids effectively prevented freeze/thaw-induced aggregation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8058650     DOI: 10.1023/a:1018948901599

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

Review 1.  Pharmaceutics of protein drugs.

Authors:  R Pearlman; T Nguyen
Journal:  J Pharm Pharmacol       Date:  1992-02       Impact factor: 3.765

2.  Conformational fluctuations and protein reactivity. Determination of the rate-constant spectrum and consequences in elementary biochemical processes.

Authors:  D Lavalette; C Tetreau; J C Brochon; A Livesey
Journal:  Eur J Biochem       Date:  1991-03-28

3.  Differential scanning calorimetric studies on bovine serum albumin: II. Effects of neutral salts and urea.

Authors:  M Yamasaki; H Yano; K Aoki
Journal:  Int J Biol Macromol       Date:  1991-12       Impact factor: 6.953

4.  Freezing denaturation of ovalbumin at acid pH.

Authors:  T Koseki; N Kitabatake; E Doi
Journal:  J Biochem       Date:  1990-03       Impact factor: 3.387

5.  Heterogeneity of the gradients performed by the freeze-thaw method.

Authors:  J J Centelles; R Franco
Journal:  J Biochem Biophys Methods       Date:  1989-05

6.  Lactate dehydrogenase from the extreme halophilic archaebacterium Halobacterium marismortui.

Authors:  K Hecht; T Langer; A Wrba; R Jaenicke
Journal:  Biol Chem Hoppe Seyler       Date:  1990-06

7.  Ultracentrifugal studies of the aggregation of human immunoglobulin G by freezing and by heating.

Authors:  U B Hansson
Journal:  Acta Chem Scand       Date:  1968

8.  Dissociation of IgG aggregates at low pH.

Authors:  R D Soltis; D Hasz
Journal:  Immunology       Date:  1982-06       Impact factor: 7.397

9.  Ribonuclease T1 is stabilized by cation and anion binding.

Authors:  C N Pace; G R Grimsley
Journal:  Biochemistry       Date:  1988-05-03       Impact factor: 3.162

10.  Radioimmunotherapy for breast cancer: treatment of a patient with I-131 L6 chimeric monoclonal antibody.

Authors:  S J DeNardo; K A Warhoe; L F O'Grady; I Hellstrom; K E Hellstrom; S L Mills; D J Macey; J E Goodnight; G L DeNardo
Journal:  Int J Biol Markers       Date:  1991 Oct-Dec       Impact factor: 3.248

View more
  21 in total

1.  Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.

Authors:  Hongwei Xie; Asish Chakraborty; Joomi Ahn; Ying Qing Yu; Deepalakshmi P Dakshinamoorthy; Martin Gilar; Weibin Chen; St John Skilton; Jeffery R Mazzeo
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

2.  A new approach to explore the impact of freeze-thaw cycling on protein structure: hydrogen/deuterium exchange mass spectrometry (HX-MS).

Authors:  Aming Zhang; Wei Qi; Satish K Singh; Erik J Fernandez
Journal:  Pharm Res       Date:  2011-02-08       Impact factor: 4.200

Review 3.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

Review 4.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 5.  Analytical comparability study of recombinant monoclonal antibody therapeutics.

Authors:  Alexandre Ambrogelly; Stephen Gozo; Amit Katiyar; Shara Dellatore; Yune Kune; Ram Bhat; Joanne Sun; Ning Li; Dongdong Wang; Christine Nowak; Alyssa Neill; Gomathinayagam Ponniah; Cory King; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

Review 6.  Forced degradation of recombinant monoclonal antibodies: A practical guide.

Authors:  Christine Nowak; Jason K Cheung; Shara M Dellatore; Amit Katiyar; Ram Bhat; Joanne Sun; Gomathinayagam Ponniah; Alyssa Neill; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

7.  Comparative study of antibody immobilization mediated by lipid and polymer fibers.

Authors:  Celine Cohn; Siu Ling Leung; Zhengbao Zha; Jessica Crosby; Weibing Teng; Xiaoyi Wu
Journal:  Colloids Surf B Biointerfaces       Date:  2015-06-19       Impact factor: 5.268

8.  Buffer-dependent fragmentation of a humanized full-length monoclonal antibody.

Authors:  Branden A Salinas; Hasige A Sathish; Ambarish U Shah; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

9.  Fragmentation of a recombinant monoclonal antibody at various pH.

Authors:  Georgeen Gaza-Bulseco; Hongcheng Liu
Journal:  Pharm Res       Date:  2008-05-13       Impact factor: 4.200

10.  Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography.

Authors:  Başak Kükrer; Vasco Filipe; Esther van Duijn; Piotr T Kasper; Rob J Vreeken; Albert J R Heck; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-08-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.